Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
LMO1 encodes a dopamine transporter which is a member of the sodium- and chloride-dependent neurotransmitter transporter family.
Showing 10 out of 20 products:
Data suggest that environment pollutants methylmercury and 1-methyl-4-phenylpyridinium decrease release of dopamine from dopaminergic neurons; this mechanism involves down-regulation of expression of Slc6a3 (show SLC6A3 Antibodies).
This study show that Dopamine transporter is enriched in filopodia and induces filopodia formation.
The sigma-1R deficiency through suppressing NR2B (show GRIN2B Antibodies) function and DAT (show SLC6A3 Antibodies) expression can reduce MPTP (show PTPN2 Antibodies)-induced death of dopaminergic neurons and parkinsonism.
DAT (show SLC6A3 Antibodies) gene knockout in mice results dendritic spine loss in pyramidal neurons in the CA1 (show CA1 Antibodies) field of the hippocampus.
Results show that moderate increases in DAT (show SLC6A3 Antibodies) function cause spontaneous dopaminergic cell loss, oxidative stress and fine motor impairment that is reversed by l-DOPA treatment
Chronic and acute reductions of DAT (show SLC6A3 Antibodies) functioning in mice impaired decision-making.
These results demonstrate that the presence of the N-terminal tag leads to impaired DAT (show SLC6A3 Antibodies) protein expression in vivo due in part to improper trafficking of the tagged transporter.
studies demonstrate an in vivo functional impact of the DAT (show SLC6A3 Antibodies) Val559 variant, providing support for the ability of DAT (show SLC6A3 Antibodies) dysfunction to impact risk for mental illness.
The data of this study imply that individual differences in DAT (show SLC6A3 Antibodies) expression (either genetically or pharmacologically induced) may affect susceptibility to addiction of different types of psychostimulants.
findings support the idea that altered DAT (show SLC6A3 Antibodies) and VMAT2 (show Slc18a2 Antibodies) expression affect age-related changes in dopaminergic function.
Increased nigral SLC6A3 activity may be a risk factor for SCZ.
DRD4 (show DRD4 Antibodies) and SLC6A3 (show SLC6A3 Antibodies) gene polymorphisms may have a role in food intake and nutritional status in children in early stages of development
Our findings suggest that rare high-risk copy number variations affecting the gene encoding the dopamine transporter contribute to the pathogenesis of schizophrenia and affective disorders.
Compared with healthy controls, opioid-dependent individuals showed a significant reduction in striatal DAT (show SLC6A3 Antibodies) density, which also negatively correlated with non-perseverative errors in working memory.
Study failed to observe a significant association of the SLC6A3 (show SLC6A3 Antibodies) 40-base pair variable number of tandem repeats polymorphism (rs28363170) with cognitive function in healthy adults
the 3'-UTR (show UTS2R Antibodies) VNTR polymorphism is significantly associated with smoking cessation, and smokers with one or more 9-repeat alleles have a 17% higher probability of smoking cessation than smokers carrying no such allele. [meta-analysis]
high SLC6A3 (show SLC6A3 Antibodies) expression in Clear cell renal cell carcinoma (show MOK Antibodies) tissue was correlated with a shorter period of recurrence-free survival following surgery.
Children without the haplotypes associated with the reduced SLC6A3 (show SLC6A3 Antibodies) gene expression and thus lower dopamine functioning appeared to demonstrate altered levels of effortful control as a function of maternal parenting quality.
Computational study providse novel insights into the role of collective dynamics in functionally relevant state-to-state transitions in DAT (show SLC6A3 Antibodies), at a level of atomistic detail
Higher levels of maternal depressive symptoms predicted reduced cortisol flexibility across challenges for infants with at least one A1 allele of DRD2 (show DRD2 Antibodies) and infants with the 10/10 genotype of SLC6A3 (show SLC6A3 Antibodies)
This gene encodes a dopamine transporter which is a member of the sodium- and chloride-dependent neurotransmitter transporter family. The 3' UTR of this gene contains a 40 bp tandem repeat, referred to as a variable number tandem repeat or VNTR, which can be present in 3 to 11 copies. Variation in the number of repeats is associated with idiopathic epilepsy, attention-deficit hyperactivity disorder, dependence on alcohol and cocaine, susceptibility to Parkinson disease and protection against nicotine dependence.
LIM domain only protein 3
, LIM domain only 3
, neuronal-specific transcription factor DAT1
, dopamine-inducible LIM-domain transcription factor DAT1
, DA transporter
, dopamine transporter 1
, sodium-dependent dopamine transporter
, solute carrier family 6 member 3
, solute carrier family 6 (neurotransmitter transporter, dopamine), member 3
, solute carrier family 6, member 3